Pharmaceuticals, Biotechnology and Life Sciences
Sandoz, a Novartis division, has acquired rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets, further reinforcing its leading global position in antibiotics. In 2020,...
Hikma Pharmaceuticals has announced it launched Micafungin for Injection through its US affiliate, Hikma Pharmaceuticals USA Inc. The company has launched 50mg and 100mg doses.
A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19. The trial, ACTIV-2, is sponsored by the National Institute of Allergy...
Researchers from the National Institutes of Health have identified and tested a drug combination that exploits a weakness in small...
An international team of scientists has found evidence that SARS-CoV-2, the virus that causes COVID-19, infects cells in the mouth....
Data presented by Professor Christophe Le Tourneau at the 2021 Annual Meeting of the American Society for Radiation Oncology First…
Early Clinical Activity and Safety Profile Support Continued Investigation of Repotrectinib in Pediatric Tumors Harboring ALK, ROS1 or NTRK Alterations…
62% vs. 25% overall response rates with navicixizumab plus paclitaxel in biomarker positive vs. biomarker negative patients using the Xerna™ TME…
BUFFALO, N.Y., Oct. 22, 2021 (GLOBE NEWSWIRE) — Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development,…
PHILADELPHIA, Oct. 22, 2021 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (the “Company”) (Nasdaq: CNTX), a women’s oncology company developing advanced…
‒ Susvimo, previously called Port Delivery System with ranibizumab, is the first wet AMD treatment in 15 years to provide…
Positive results from two cohorts of Phase 1/2 clinical trial with NOX-A12 in brain cancer; full readout expected in Q1…
DUBLIN–(BUSINESS WIRE)–The “Transfection Reagents and Equipment Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)” report has been…
DUBLIN–(BUSINESS WIRE)–The “Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026” report has been added to ResearchAndMarkets.com’s offering.…
Sixteen-week results from the Phase 3 ECZTRA 6 trial in adolescents showed tralokinumab 150 mg and 300 mg significantly improved…